As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.

Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million. 

Cambridge, Massachusetts-based Alnylam Pharmaceuticals released positive Phase III data from the ILLUMINATE-A clinical trial of lumasiran in the treatment of primary hyperoxaluria type 1 (PH1).

One of the companies working on the cutting edge of the field of gene silencing is Pasadena, California-based Arrowhead Pharmaceuticals, which expectS 2020 to be a real inflection point.

Alnylam’s gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study, bringing the company a step closer to marketing the first approved treatment for the condition.

Alnylam Pharmaceuticals Inc. priced the company’s gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval.

The U.S. Food and Drug Administration accepted Alnylam Pharmaceuticals Inc.’s New Drug Application for givosiran – an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 in development for the treatment of acute hepatic porphyria – and granted Priority Review for the NDA.